Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 15,608 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin and Connective Tissue Disease Clear all
Withdrawn No phase listed Observational

Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection

NCT00811863
View directory record Official record
Conditions
Nephrogenic Systemic Fibrosis, Renal Insufficiency
Interventions
Not listed
Lead sponsor
Guerbet
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 31, 2026, 1:25 AM EDT
Completed No phase listed Observational

Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma

NCT00745862
View directory record Official record
Conditions
Melanoma
Interventions
questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 31, 2026, 1:25 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer

NCT00593827
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ixabepilone
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 31, 2026, 1:25 AM EDT
Terminated Phase 1 Interventional

A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

NCT05080842
View directory record Official record
Conditions
Breast Cancer
Interventions
AC682
Drug
Lead sponsor
Accutar Biotechnology Inc
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 31, 2026, 1:25 AM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

NCT00074269
View directory record Official record
Conditions
Breast Cancer
Interventions
anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, melphalan, methotrexate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 31, 2026, 1:25 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

NCT06362369
View directory record Official record
Conditions
Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
Interventions
Alintegimod, Ipilimumab, Nivolumab
Drug
Lead sponsor
7 Hills Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Completed Phase 2 Interventional

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

NCT01480583
View directory record Official record
Conditions
Breast Cancer, Brain Metastases
Interventions
GRN1005, Trastuzumab, 18F-FLT
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Harvey, Illinois • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 31, 2026, 1:25 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 31, 2026, 1:25 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

NCT02764541
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Tamoxifen, Palbociclib, Endocrine Therapy
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
11
States / cities
Stamford, Connecticut • Brewer, Maine • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

NCT07261631
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Soft Tissue Sarcoma
Interventions
68Ga-NNS309, 177Lu-DFC413
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Terminated Phase 2 Interventional Results available

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

NCT01586195
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 31, 2026, 1:25 AM EDT
Completed Phase 2 Interventional Results available

NSAID Effects on Clinical and Imaging Breast Biomarkers

NCT01761877
View directory record Official record
Conditions
Inflammation, Cancer, Pain, Hypertension
Interventions
Sulindac
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
Up to 75 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Tucson, Arizona • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 31, 2026, 1:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

NCT02837575
View directory record Official record
Conditions
Herpes Genitalis
Interventions
VCL-HB01, Phosphate-buffered saline
Biological · Other
Lead sponsor
Vical
Industry
Eligibility
18 Years to 50 Years
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 31, 2026, 1:25 AM EDT
Completed Phase 2 Interventional

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

NCT03897257
View directory record Official record
Conditions
Tinea Pedis
Interventions
UHE-103A1 cream, UHE-103A2 cream, UHE-103B cream, UHE-103A1B cream, UHE-103A2B cream
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
San Diego, California • Melbourne, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 31, 2026, 1:25 AM EDT
Completed Phase 1 Interventional Results available

Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

NCT04128579
View directory record Official record
Conditions
Lupus Erythematosus, Lupus Nephritis
Interventions
Itolizumab [Bmab 600]
Drug
Lead sponsor
Biocon Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
19
States / cities
Sun City, Arizona • Chula Vista, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Completed Phase 2 Interventional Results available

MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

NCT03406962
View directory record Official record
Conditions
Inherited Metabolic Disorders (IMD)
Interventions
MGTA-456
Drug
Lead sponsor
Magenta Therapeutics, Inc.
Industry
Eligibility
0 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 31, 2026, 1:25 AM EDT
Completed No phase listed Observational

Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis

NCT00001541
View directory record Official record
Conditions
Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 1:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients

NCT01876329
View directory record Official record
Conditions
Vitamin B12 Deficiency
Interventions
Not listed
Lead sponsor
Keesler Air Force Base Medical Center
Federal
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Keesler Air Force Base, Mississippi
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 31, 2026, 1:25 AM EDT
Terminated Early Phase 1 Interventional

Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer

NCT01138553
View directory record Official record
Conditions
Invasive Breast Cancer, Ductal Carcinoma in Situ
Interventions
Mifepristone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 31, 2026, 1:25 AM EDT
Completed Phase 1 Interventional

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

NCT05727839
View directory record Official record
Conditions
Cutaneous Tumor, Malignant Solid Tumor
Interventions
JCXH-211 Injection
Drug
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Completed Not applicable Interventional

Integrated Intervention for Breast Cancer Survivors With Diabetes

NCT05092477
View directory record Official record
Conditions
Diabetes, Breast Cancer
Interventions
Integrated Intervention for Breast Cancer Survivors with Diabetes, Attention Control
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • New Hyde Park, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 31, 2026, 1:25 AM EDT
Completed No phase listed Observational

Weight Loss Counseling for African American Women Who Are Breast Cancer Survivors

NCT00872677
View directory record Official record
Conditions
Breast Cancer, Obesity, Weight Changes
Interventions
Diet, Spiritual counseling
Behavioral · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 31, 2026, 1:25 AM EDT
Completed No phase listed Observational

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

NCT02910557
View directory record Official record
Conditions
Melanoma, Herpetic Infection
Interventions
Not listed
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
9
States / cities
Coral Springs, Florida • Baltimore, Maryland • Jefferson City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 31, 2026, 1:25 AM EDT
Completed Phase 2 Interventional Results available

Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients

NCT00428922
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, Bevacizumab, Docetaxel
Drug
Lead sponsor
Bhuvaneswari Ramaswamy
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Cleveland, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 31, 2026, 1:25 AM EDT